Everything tagged "healthcare" across the TickerSpark archives.
Ensign combines strong revenue and EPS growth with improving clinical outcomes and disciplined acquisitions. The stock looks attractive operationally, but its premium valuation and reimbursement mix keep the upside tied to continued execution.
Cooper Companies posted 8% revenue growth and 26% non-GAAP EPS growth in Q2, with premium contact lenses and fertility driving the story. A strategic review at CooperSurgical adds a potential value catalyst, while debt and Asia Pacific weakness keep the risk profile moderate.
Biotech’s sharp outperformance is real, but the rally is rewarding profitable franchises and identifiable catalysts rather than lifting the entire sector. The better opportunity is selective exposure to de-risked pipelines, not indiscriminate bets on biotech as technology’s replacement.
Medtronic is shifting from a slow-growth story to an execution-led reacceleration, with broad-based Q1 strength across cardiovascular, neuroscience, and medical surgical. The stock earns a Buy as growth platforms like Affera, Hugo, and Micra support a fair value of $99.
Abivax is a catalyst-driven biotech centered on obefazimod, with long-term ulcerative colitis durability data and a cash runway into Q4 2027. The stock offers meaningful upside if Phase 3 execution holds, but the valuation already prices in a lot of success.
Novartis is navigating Entresto generic pressure with strong growth from Kisqali, Pluvicto, Leqvio, and Kesimpta. The stock looks durable, but valuation and near-term earnings pressure keep the stance at Hold.
Biomerica's $2.23 million financing extends its runway, but it adds roughly 30% to the pre-deal share count without proving the business is turning. With severe losses, negative cash flow, and the stock still below its 200-day average, BMRA remains a dilution trade rather than a turnaround.
Summit Therapeutics is a high-risk, high-upside oncology story centered on ivonescimab and a November 2026 FDA decision. The stock offers meaningful regulatory upside, but the business still has no product revenue and remains dependent on one drug.
Phibro Animal Health Corporation (PAHC) gained after a strong earnings beat, but the bigger story is the depth behind it: profit growth outpaced revenue, Animal Health led segment momentum, and management raised fiscal 2026 and 2027 guidance above consensus, reinforcing the bullish setup.
Agilent Technologies, Inc. (A) gains after a stronger-than-expected quarter, with EPS and revenue both topping estimates. Our deep-dive looks beyond the headline beat at end-market momentum, guidance lift, tariff offsets, and the demand signals behind the after-hours move.
Agilent posted 6.3% core growth, 14% EPS growth, and raised FY26 guidance, but the stock still needs continued execution at 23.0x forward earnings.
Phibro Animal Health is executing well after the Zoetis portfolio acquisition, with double-digit sales and EBITDA growth. But elevated leverage and regulatory exposure keep the stock in Hold territory.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime